260
Participants
Start Date
April 17, 2008
Primary Completion Date
December 31, 2009
Study Completion Date
February 28, 2010
Tetravalent CYD Dengue Vaccine , 5555 formulation
A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
Tetravalent CYD Dengue Vaccine , 5553 formulation
A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
Tetravalent CYD Dengue Vaccine, 4444 formulation
A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
Investigational Site 004, Hoover
Investigational Site 003, Springfield
Investigational Site 001, New Orleans
Investigational Site 002, San Diego
Investigational Site 005, Vallejo
Lead Sponsor
Sanofi
INDUSTRY